Published in Alzheimer Dis Assoc Disord on February 22, 2006
Hemiarthroplasty or internal fixation for intracapsular displaced femoral neck fractures: randomised controlled trial. BMJ (2007) 1.98
Evaluating the cost effectiveness of donepezil in the treatment of Alzheimer's disease in Germany using discrete event simulation. BMC Neurol (2012) 1.39
Performance of the EQ-5D and the EQ-5D+C in elderly patients with cognitive impairments. Health Qual Life Outcomes (2007) 1.14
Capabilities and quality of life in Dutch psycho-geriatric nursing homes: an exploratory study using a proxy version of the ICECAP-O. Qual Life Res (2011) 1.09
The independent contribution of executive functions to health related quality of life in older women. BMC Geriatr (2010) 1.04
Diagnostic and economic evaluation of new biomarkers for Alzheimer's disease: the research protocol of a prospective cohort study. BMC Neurol (2012) 0.92
Act In case of Depression: the evaluation of a care program to improve the detection and treatment of depression in nursing homes. Study Protocol. BMC Psychiatry (2011) 0.89
Early intervention in Alzheimer's disease: a health economic study of the effects of diagnostic timing. BMC Neurol (2014) 0.89
Impact of post-stroke cognitive impairment with no dementia on health-related quality of life. J Stroke (2013) 0.85
Cognitive impairment and preferences for current health. Health Qual Life Outcomes (2009) 0.84
Generic quality of life assessment in dementia patients: a prospective cohort study. BMC Neurol (2010) 0.84
Grip on challenging behaviour: a multidisciplinary care programme for managing behavioural problems in nursing home residents with dementia. Study protocol. BMC Health Serv Res (2011) 0.83
Quality of life in dementia: a study on proxy bias. BMC Med Res Methodol (2013) 0.83
SveDem, the Swedish Dementia Registry - a tool for improving the quality of diagnostics, treatment and care of dementia patients in clinical practice. PLoS One (2015) 0.83
Health state valuation in mild to moderate cognitive impairment: feasibility of computer-based, direct patient utility assessment. Med Decis Making (2008) 0.78
Florbetaben PET in the Early Diagnosis of Alzheimer's Disease: A Discrete Event Simulation to Explore Its Potential Value and Key Data Gaps. Int J Alzheimers Dis (2012) 0.77
Agreement between Patient and Proxy Assessments of Quality of Life among Older Adults with Vascular Cognitive Impairment Using the EQ-5D-3L and ICECAP-O. PLoS One (2016) 0.77
How does the canadian general public rate moderate Alzheimer's disease? J Aging Res (2011) 0.77
Visual analogue scales: scale recalibration by patients with dementia and their proxies. Qual Life Res (2012) 0.77
Family composition and expressions of family-focused care needs at an academic memory disorders clinic. Int J Alzheimers Dis (2013) 0.76
Deep brain stimulation for Alzheimer disease: a decision and cost-effectiveness analysis. J Neurol (2015) 0.76
Patient-rated versus proxy-rated cognitive and functional measures in older adults. Patient Relat Outcome Meas (2017) 0.75
Cost-effectiveness of one year dementia follow-up care by memory clinics or general practitioners: economic evaluation of a randomised controlled trial. PLoS One (2013) 0.75
A single-blind, pilot randomised trial of a weight management intervention for adults with intellectual disabilities and obesity: study protocol. Pilot Feasibility Stud (2015) 0.75
Gender-dependence of substituted judgment on quality of life in patients with dementia. BMC Neurol (2011) 0.75
Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet (2009) 14.86
Mild cognitive impairment. Lancet (2006) 10.21
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement (2013) 7.69
CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA (2009) 7.29
An active and socially integrated lifestyle in late life might protect against dementia. Lancet Neurol (2004) 5.78
Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study. Lancet (2006) 5.34
Protective variant for hippocampal atrophy identified by whole exome sequencing. Ann Neurol (2015) 5.10
Alzheimer's disease: clinical trials and drug development. Lancet Neurol (2010) 4.65
Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study. Lancet Neurol (2006) 4.54
The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol (2005) 4.54
Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch Neurol (2005) 4.49
Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem (2004) 4.23
Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors. Lancet Neurol (2008) 4.14
CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain (2006) 3.95
Leisure-time physical activity at midlife and the risk of dementia and Alzheimer's disease. Lancet Neurol (2005) 3.95
Late-life engagement in social and leisure activities is associated with a decreased risk of dementia: a longitudinal study from the Kungsholmen project. Am J Epidemiol (2002) 3.70
Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol (2009) 3.65
Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch Gen Psychiatry (2010) 3.64
Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol (2009) 3.34
The magnitude of dementia occurrence in the world. Alzheimer Dis Assoc Disord (2003) 3.23
The worldwide economic impact of dementia 2010. Alzheimers Dement (2013) 3.23
Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. Lancet Neurol (2007) 3.22
Twenty-year changes in dementia occurrence suggest decreasing incidence in central Stockholm, Sweden. Neurology (2013) 3.20
Fast and robust multi-atlas segmentation of brain magnetic resonance images. Neuroimage (2009) 3.13
Heart failure and risk of dementia and Alzheimer disease: a population-based cohort study. Arch Intern Med (2006) 2.90
Prevalence of chronic diseases and multimorbidity among the elderly population in Sweden. Am J Public Health (2008) 2.86
The worldwide societal costs of dementia: Estimates for 2009. Alzheimers Dement (2010) 2.75
Pulse pressure and risk of Alzheimer disease in persons aged 75 years and older: a community-based, longitudinal study. Stroke (2003) 2.60
Small vessel disease and general cognitive function in nondisabled elderly: the LADIS study. Stroke (2005) 2.59
Progression of white matter hyperintensities and incidence of new lacunes over a 3-year period: the Leukoaraiosis and Disability study. Stroke (2008) 2.57
Patterns of chronic multimorbidity in the elderly population. J Am Geriatr Soc (2009) 2.54
Hippocampus and entorhinal cortex in mild cognitive impairment and early AD. Neurobiol Aging (2004) 2.49
Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann Intern Med (2002) 2.41
Relation of education and occupation-based socioeconomic status to incident Alzheimer's disease. Am J Epidemiol (2004) 2.35
The brain injury biomarker VLP-1 is increased in the cerebrospinal fluid of Alzheimer disease patients. Clin Chem (2008) 2.35
The amyloid beta-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae. Proc Natl Acad Sci U S A (2008) 2.30
Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study. Lancet Neurol (2012) 2.22
A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease. Int J Geriatr Psychiatry (2004) 2.21
Mental, physical and social components in leisure activities equally contribute to decrease dementia risk. Dement Geriatr Cogn Disord (2005) 2.19
Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B. Arch Neurol (2008) 2.19
The use of cholinesterase inhibitors and the risk of myocardial infarction and death: a nationwide cohort study in subjects with Alzheimer's disease. Eur Heart J (2013) 2.15
Incidence and risk factors for mild cognitive impairment: a population-based three-year follow-up study of cognitively healthy elderly subjects. Dement Geriatr Cogn Disord (2004) 2.12
Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. Arch Gen Psychiatry (2004) 2.07
[Cognitive medicine--field of knowledge for future specialist education]. Lakartidningen (2008) 2.03
Association between mid-life marital status and cognitive function in later life: population based cohort study. BMJ (2009) 2.00
Measurement of alpha- and beta-secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patients. Exp Neurol (2003) 1.99
The association of inappropriate drug use with hospitalisation and mortality: a population-based study of the very old. Drugs Aging (2005) 1.97
CSF Abeta42, Tau and phosphorylated Tau, APOE epsilon4 allele and MCI type in progressive MCI. Neurobiol Aging (2006) 1.96
A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease--rivastigmine patch versus capsule. Int J Geriatr Psychiatry (2007) 1.92
Impact of age-related cerebral white matter changes on the transition to disability -- the LADIS study: rationale, design and methodology. Neuroepidemiology (2005) 1.92
Impact of white matter hyperintensities scoring method on correlations with clinical data: the LADIS study. Stroke (2006) 1.88
The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement (2011) 1.87
Confounding factors influencing amyloid Beta concentration in cerebrospinal fluid. Int J Alzheimers Dis (2010) 1.86
Person-centred care of people with severe Alzheimer's disease: current status and ways forward. Lancet Neurol (2008) 1.86
An estimate of the total worldwide societal costs of dementia in 2005. Alzheimers Dement (2007) 1.83
Multi-method analysis of MRI images in early diagnostics of Alzheimer's disease. PLoS One (2011) 1.79
A longitudinal study integrating population, care and social services data. The Swedish National study on Aging and Care (SNAC). Aging Clin Exp Res (2004) 1.78
Mild cognitive impairment in the general population: occurrence and progression to Alzheimer disease. Am J Geriatr Psychiatry (2008) 1.77
On the etiology of incident brain lacunes: longitudinal observations from the LADIS study. Stroke (2008) 1.75
Amyloid and tau proteins in cortical brain biopsy and Alzheimer's disease. Ann Neurol (2010) 1.74
Increased fMRI responses during encoding in mild cognitive impairment. Neurobiol Aging (2006) 1.74
Serum lipids and hippocampal volume: the link to Alzheimer's disease? Ann Neurol (2004) 1.72
Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease. Brain Res Mol Brain Res (2003) 1.70
Radial width of the temporal horn: a sensitive measure in Alzheimer disease. AJNR Am J Neuroradiol (2002) 1.66
Anaemia increases the risk of dementia in cognitively intact elderly. Neurobiol Aging (2006) 1.65
Late-life body mass index and dementia incidence: nine-year follow-up data from the Kungsholmen Project. J Am Geriatr Soc (2007) 1.65
Detection of Alzheimer's disease and dementia in the preclinical phase: population based cohort study. BMJ (2003) 1.65
Up-regulation of phosphorylated/activated p70 S6 kinase and its relationship to neurofibrillary pathology in Alzheimer's disease. Am J Pathol (2003) 1.64
Safety and efficacy of galantamine (Reminyl) in severe Alzheimer's disease (the SERAD study): a randomised, placebo-controlled, double-blind trial. Lancet Neurol (2008) 1.63
Visual presentation of novel objects and new spatial arrangements of objects differentially activates the medial temporal lobe subareas in humans. Eur J Neurosci (2004) 1.63
The effect of borderline diabetes on the risk of dementia and Alzheimer's disease. Diabetes (2007) 1.62
Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss? Neurosci Lett (2008) 1.60
Neurofilament inclusion body disease: a new proteinopathy? Brain (2003) 1.59
Incidence of stroke in people with Alzheimer disease: a national register-based approach. Neurology (2013) 1.55
Differential evolution of cognitive impairment in nondemented older persons: results from the Kungsholmen Project. Am J Psychiatry (2002) 1.55
Frontotemporal dementia as a neural system disease. Neurobiol Aging (2005) 1.55
A comparison between the accuracy of voxel-based morphometry and hippocampal volumetry in Alzheimer's disease. J Magn Reson Imaging (2004) 1.54
Longitudinal stability of CSF biomarkers in Alzheimer's disease. Neurosci Lett (2007) 1.54
Levels of mTOR and its downstream targets 4E-BP1, eEF2, and eEF2 kinase in relationships with tau in Alzheimer's disease brain. FEBS J (2005) 1.54
Partial purification and characterization of gamma-secretase from post-mortem human brain. J Biol Chem (2003) 1.54
Diffusion tensor imaging and tract-based spatial statistics in Alzheimer's disease and mild cognitive impairment. Neurobiol Aging (2009) 1.53
Risk of rapid global functional decline in elderly patients with severe cerebral age-related white matter changes: the LADIS study. Arch Intern Med (2007) 1.52
iTRAQ and multiple reaction monitoring as proteomic tools for biomarker search in cerebrospinal fluid of patients with Parkinson's disease dementia. Exp Neurol (2012) 1.52